Group 1 - The company has received the clinical trial approval notice for "Yunpi Huatan Tongqiao Granules" from the National Medical Products Administration, allowing it to conduct clinical trials for treating adenoid hypertrophy in children [1][2] - The granules are indicated for symptoms associated with adenoid hypertrophy, including snoring, mouth breathing, nasal congestion, and fatigue, with preclinical studies showing significant therapeutic effects [1][2] - The prevalence of adenoid hypertrophy in children aged 2 to 12 is approximately 46.42%, with an increasing trend, highlighting a significant market opportunity for the product if successfully launched [2] Group 2 - Current treatments for adenoid hypertrophy primarily include chemical medications such as nasal corticosteroids and leukotriene receptor antagonists, with no approved traditional Chinese medicine products available, indicating a clinical gap that the new product could fill [2] - The company must complete clinical trials and obtain further approvals from the National Medical Products Administration before the product can be manufactured and marketed [2]
江苏康缘药业股份有限公司 关于收到运脾化痰通窍颗粒临床试验批准通知书的公告